ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry

- ADOCIA recognized with prestigious Frost & Sullivan award for its innovative BioChaperone® technology for therapeutic proteins formulation
- Frost and Sullivan also credits ADOCIA’s distinctive strategy of “Innovative Medicines for Everyone, Everywhere” as a strong model to deliver innovation to both western and emerging markets

Lyon (France), September 30, 2014 - ADOCIA (Euronext Paris : FR0011184241 - ADOC) announces today it has been awarded the 2014 Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins industry. Frost & Sullivan cited ADOCIA for combining technology excellence with visionary innovation while evolving in a very competitive industry. ADOCIA’s core technology BioChaperone® is an innovative, heparin-inspired, molecular delivery system of therapeutic protein, which is designed to enhance their safety and effectiveness. The library currently contains 300 compounds that can be adapted to different proteins.

Frost & Sullivan noted that “ADOCIA has excelled in the development of a novel technology capable of being tailor-made for each protein” and that “BioChaperone remarkably contributes to the improvement of hormones, growth factors and monoclonal antibodies”. The firm praised ADOCIA for introducing the concept of “Innovative Medicine for Everyone, Everywhere”, which “nicely aligns with global health, wellness and wellbeing Mega Trends”. Frost & Sullivan analyst Cecilia Van Cauwenberghe specifically noted that “[ADOCIA] constantly strategizes to boost the suitability and ease of use of BioChaperone so as to make the therapeutic proteins in the market accessible to the masses”.

Frost and Sullivan commended ADOCIA for being ready to expand its fields of expertise, as recently shown with the licensing-in of DriveIn®, a nanotechnology for drug delivery in oncology. Cecilia Van Cauwenberghe writes: “ADOCIA has early envisioned the future and has pioneered the development of alternative solutions to worldwide healthcare concerns such as diabetes, cancer disease and inflammation”.

Commenting on the award, Gérard Soula, Chief Executive Officer of ADOCIA said: “We are delighted to receive this prestigious award, which recognizes both our long-term strategy and the value of our core technology. Taking advantage of our partner-oriented model, we aim to rapidly bring affordable innovation to patients both in emerging and western countries, fulfilling our motto of Innovative Medicine for everyone, everywhere.”
The award was announced in the wake of ADOCIA releasing positive data from a Phase IIa dose-response study of its lead product BioChaperone Lispro, an ultra-fast formulation of prandial insulin lispro (Eli Lilly’s Humalog®). Indeed, ADOCIA has built a strong clinical pipeline relying on BioChaperone technology, including three insulin products for the treatment of diabetes, now in Phase II clinical trials, and an innovative formulation of a growth factor for the treatment of chronic wounds, currently in Phase III. "With positive clinical data gathered on four different products and two indications, BioChaperone technology is now entering a phase of maturity, and I consider this award as a very welcome endorsement of our scientific and clinical expertise as well as our commitment to serve patients everywhere.” said Olivier Soula, Deputy General Manager and R&D Director of ADOCIA.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

• **The Integrated Value Proposition** provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.

• **The Partnership Infrastructure** is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion

About ADOCIA
**To be a global leader in the innovative delivery of insulins and therapeutic proteins**
ADOCIA is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. It has a particularly strong expertise in the field of insulins. ADOCIA’s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients.

ADOCIA has successfully completed two Phase I and IIa studies of a fast-acting human insulin formulation (HinsBet®), one Phase I and two Phase IIa studies of an ultra-fast-acting insulin lispro (BioChaperone® Lispro U100) and a Phase I/II of a unique combination of insulin glargine, the gold-standard of basal insulin and insulin lispro, a fast-acting insulin analog (BioChaperone® Combo). A Phase IIa study of HinsBet is ongoing and a dose-escalation Phase IIa study of BioChaperone Combo is scheduled for the fourth quarter 2014. The company is also preparing a first clinical study of a new ultra-fast concentrated insulin formulation based on insulin lispro for 2015.

ADOCIA also completed one Phase I/II clinical study of its product based on PDGF-BB for treating diabetic foot ulcer (BC PDGF-BB). A Phase III clinical study was launched in India in August 2014.

ADOCIA has extended its activities to the formulation of monoclonal antibodies, which are gold-standard biologics for the treatment of various chronic pathologies (cancer, inflammation, etc.). ADOCIA is engaged in collaborative programs with two major pharmaceutical companies in this field.
Fighting cancer with targeted treatments
DriveIn® is a nanotechnology which is remarkably efficient in delivering active compounds into cancer cells. This new platform constitutes an exceptional opportunity to enter the oncology market by improving the efficacy of both already approved treatments and novel proprietary molecules.

“Innovative medicine for everyone, everywhere”
ADOCIA’s therapeutic innovations aim to provide solutions in a profoundly changing global pharmaceutical and economic context, characterized by (i) an increased prevalence and impact of the targeted pathologies, (ii) a growing and ageing population, (iii) a need to control public health expenditures and (iv) an increasing demand from emerging countries.

ADOCIA is listed on the regulated market of Euronext Paris (ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA, ADOC.FP) and is included in the Next Biotech index. American Depositary Receipts representing ADOCIA common stock are traded on the US OTC market under the ticker symbol ADOCY. For more information, visit www.adocia.com

Disclaimer
This press release contains certain forward-looking statements concerning ADOCIA and its business. Such forward-looking statements are based on assumptions that ADOCIA considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the ‘Risk Factors’ section of the Reference Document registered by the Autorite des marches financiers on April 24, 2014 under number R.14-020 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which ADOCIA operates. The forward-looking statements contained in this press release are also subject to risks not yet known to ADOCIA or not currently considered material by ADOCIA. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of ADOCIA to be materially different from such forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy ADOCIA shares in any jurisdiction.

Contact ADOCIA
Gerard Soula - contactinvestisseurs@adocia.com
Chairman and CEO of ADOCIA
Tel.: +33 4 72 610 610

Press Relations
ALIZE RP
Caroline Carmagnol
caroline@alizerp.com
adocia@alizerp.com
Tel.: +33 170 225 390

Contact Frost & Sullivan
Kristina Menzefricke
Best Practices
Frost & Sullivan
kristina.menzefricke@frost.com
P: +44 (0)20 7915 7869